Pete Williams is one of few researchers in Sweden concentrating on glaucoma. The goal is an effective treatment, something that stops the degenerative process in the nerve cells of the eye. Williams ...

Scientists from Trinity College Dublin have developed a highly promising gene therapy to treat glaucoma, a debilitating eye condition that can lead to complete vision loss, and which affects around 80 ...

Leveraging Northway Biotech's 20+ years of CDMO expertise, Diorasis Therapeutics is advancing DT003, a single-dose AAV gene therapy for glaucoma. As part of the collaboration, Northway Biotech will ...

Scientists from Trinity College Dublin have developed a highly promising gene therapy to treat glaucoma – a debilitating eye condition that can lead to complete vision loss, and which affects around ...

Modern glaucoma treatments can only preserve a patient’s current level of vision, offering no hope of restoration. A new Phase 1 clinical trial is using gene therapy that could turn back the clock on ...

Kolkata, 23 July 2026 — Premas Life Sciences, through its precision genomics brand Uncoded, participated in the Genetics-enabled Social Innovation for Glaucoma Health & Treatment (GENE-SIGHT) ...

Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by high pressure inside the eye. Patients often rely on daily eye drops to ...

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...